Cancer Research UK logo.
SearchDonate
  • Search

A study looking at biomarkers before and after surgery of the prostate, bladder, penis or kidney

Overview

Cancer types:

Bladder cancer, Kidney cancer, Penile cancer, Prostate cancer

Status:

Open

Phase:

Other

Details

Surgery is a treatment for cancer and non cancerous (benign) conditions of the prostate, bladder, penis and kidney. The number of people having this type of surgery is increasing.

This means that more people are at risk of complications after surgery. For example, bleeding and infection. Also, an increasing number of those people with cancer have cancer that comes back (recurrence) or continues to grow.

Doctors would like to find ways to monitor patients more closely. It would be useful to predict who is going to have a problem or complication after their treatment. And who is more likely to have recurrence.

Recruitment start: 1 September 2015

Recruitment end: 23 December 2026

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Stephen Fôn Hughes

Professor Iqbal Shergill

Supported by

Institute of Biomedical Science (IBMS)

NIHR Clinical Research Network: Cancer

Betsi Cadwaladr University Health Board (BCUHB)

Health & Care Research Wales

Last reviewed: 17 Jul 2025

CRUK internal database number: 12583

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Questions for your doctor

What to ask your doctor about clinical trials.

An icon of two speech bubbles, indicating a conversation.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.